Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Herceptin
Herceptin 150 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-090902 · Präparat HOS-084155
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-
paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or
4 mg/kg IV loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w IV, respectively).
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13
dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this
metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage d0ab2b38e2dd82f9f43fc20111cc60957425df25ade130000731e522cd03fbc6 · Zeichen 276–862 im Abschnitt
Wechselwirkungen · Herceptin
Herceptin 150 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-090909 · Präparat HOS-084155
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study
(H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II
studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women
with HER2-positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with
Herceptin, paclitaxel and doxorubicin to trastuzumab PK data in studies where Herceptin was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage 18fed877413ea053f5f860995d67b670727bcf7873c907cc43f4c456d3102050 · Zeichen 2523–3489 im Abschnitt
Wechselwirkungen · Herceptin
Herceptin 600 mg solution for injection in vial · Abschnitt 4.5 · PDF-Seite 40
HOS-090951 · Präparat HOS-084155
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-
paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or
4 mg/kg IV loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w IV, respectively).
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13
dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this
metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage d0ab2b38e2dd82f9f43fc20111cc60957425df25ade130000731e522cd03fbc6 · Zeichen 276–862 im Abschnitt
Wechselwirkungen · Herceptin
Herceptin 600 mg solution for injection in vial · Abschnitt 4.5 · PDF-Seite 40
HOS-090956 · Präparat HOS-084155
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study
(H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II
studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women
with HER2-positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with
Herceptin, paclitaxel and doxorubicin to trastuzumab PK data in studies where Herceptin was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage 18fed877413ea053f5f860995d67b670727bcf7873c907cc43f4c456d3102050 · Zeichen 2464–3430 im Abschnitt
Wechselwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-138161 · Präparat HOS-098156
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2 positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites
6-α hydroxylpaclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab
(8 mg/kg or 4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous,
respectively). However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite,
(7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the
elevation of this metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 024a484aab210edf50d2b49499f9573ae25ab31afad48e08332bb0fa920fc941 · Zeichen 279–881 im Abschnitt
Wechselwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9–10
HOS-138170 · Präparat HOS-098156
9
women with HER2 positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2 positive MBC were treated concomitantly with
trastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where trastuzumab was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage a097cd840810ce681ca6dc25faa27547d7c6372e616f756d8c75aac43708bc0f · Zeichen 2868–3559 im Abschnitt
Wechselwirkungen · Trazimera
Trazimera 150 mg powder for concentrate for solution for infusion Trazimera 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-139504 · Präparat HOS-098360
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α
hydroxyl-paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab
(8 mg/kg or 4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w
intravenous dose, respectively). However, trastuzumab may elevate the overall exposure of one
doxorubicin metabolite, (7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the
clinical impact of the elevation of this metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T10:10:00Z · SHA-256 9fdaf2b6f4270ea70563d54731dd8a8b47224a5c6f4970a6433712c7e0145f3f · Passage 0c533c5b489a35a3cb3bc6d66e2c1d60e0164cef2e5809f05e389e6237157f9f · Zeichen 278–886 im Abschnitt
Wechselwirkungen · Trazimera
Trazimera 150 mg powder for concentrate for solution for infusion Trazimera 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-139509 · Präparat HOS-098360
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III
study (H0648g) in which patients were treated concomitantly with trastuzumab and paclitaxel and
two Phase II studies in which trastuzumab was administered as monotherapy (W016229 and
MO16982), in women with HER2-positive MBC indicates that individual and mean trastuzumab
trough serum concentrations varied within and across studies but there was no clear effect of the
concomitant administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of
trastuzumab PK data from study M77004 in which women with HER2-positive MBC were treated
concomitantly with trastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where
trastuzumab was administered as monotherapy (H0649g) or in combination with anthracycline plus
cyclophosphamide or paclitaxel (study H0648g), suggested no effect of doxorubicin and paclitaxel
on the pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cyclophosphamide (HOS-084539) paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T10:10:00Z · SHA-256 9fdaf2b6f4270ea70563d54731dd8a8b47224a5c6f4970a6433712c7e0145f3f · Passage bded9f68aa15b7d6afb3f91fc74c5746ec5906916e5afbc45614fd37856a855d · Zeichen 2546–3520 im Abschnitt
Wechselwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.5 · PDF-Seite 9
HOS-146994 · Präparat HOS-099594
PK data from studies BO15935 and M77004 in women with HER2-positive metastatic breast cancer
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α
hydroxylpaclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab
(8 mg/kg or 4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous,
respectively). However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite,
(7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the
elevation of this metabolite were unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage f9789a535e1cfd9be5a60d55c2843533ce8fdc2b10fa62c1a42f2e84fc3ffaea · Zeichen 1255–1866 im Abschnitt
Wechselwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.5 · PDF-Seite 9
HOS-147000 · Präparat HOS-099594
Comparison of trastuzumab PK data from Study M77004 in which women with HER2-positive
metastatic breast cancer were treated concomitantly with trastuzumab, paclitaxel and doxorubicin to
trastuzumab PK data in studies where trastuzumab was administered as monotherapy (H0649g) or in
combination with anthracycline plus cyclophosphamide or paclitaxel (Study H0648g), suggested no
effect of doxorubicin and paclitaxel on the pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxorubicin (HOS-084538) cyclophosphamide (HOS-084539) paclitaxel (HOS-087959)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage 95ff5cb601c8bbd973b91bff84486d8ca31f53a7054ab42b88db56a358913fc5 · Zeichen 4086–4540 im Abschnitt
Wechselwirkungen · Herwenda
Herwenda 150 mg powder for concentrate for solution for infusion Herwenda 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-149367 · Präparat HOS-100044
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2 positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α
hydroxyl- paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab
(8 mg/kg or 4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous,
respectively). However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite,
(7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the
elevation of this metabolite were unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T17:30:00Z · SHA-256 0420b6f06ca3e337d4516096fe98f47fc8d3f966fddcad79ddc2566b63477530 · Passage ffcb90678b6ec2cdfe9ada163623d7b708d13e81ca8033e7f57a7ab8194fcf78 · Zeichen 279–884 im Abschnitt
Wechselwirkungen · Herwenda
Herwenda 150 mg powder for concentrate for solution for infusion Herwenda 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-149372 · Präparat HOS-100044
Comparison of PK results from two phase II studies (BO15935 and M77004) and one phase III study
(H0648g) in which patients were treated concomitantly with trastuzumab and paclitaxel and two
phase II studies in which trastuzumab was administered as monotherapy (W016229 and MO16982), in
women with HER2 positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2 positive MBC were treated concomitantly with
trastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where trastuzumab was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paclitaxel (HOS-087959) doxorubicin (HOS-084538) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T17:30:00Z · SHA-256 0420b6f06ca3e337d4516096fe98f47fc8d3f966fddcad79ddc2566b63477530 · Passage c1404a63a6c5646283efb7a4e2435d0a6e12364ea6754e4a28abae52a6759694 · Zeichen 2534–3508 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.